Literature DB >> 1289171

Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat.

R Fabia1, A Ar'Rajab, R Willén, R Andersson, B Ahrén, K Larsson, S Bengmark.   

Abstract

The therapeutic effects of exogenous phosphatidylcholine and phosphatidylinositol on acetic acid-induced colitis in rats were evaluated. A uniform colitis developed 4 days after instillation of 4% acetic acid for 15 s in an excluded colonic segment, also resulting in a 6-fold increase in mucosal permeability. Instillation of 12.5 mg phosphatidylcholine once daily from the day after acetic acid instillation and for the following 2 days prevented partially the development of colitis causing partial mucosal restoration. By increasing the phosphatidylcholine dose to 25 and 50 mg, a better preventive effect was achieved. By starting the phosphatidylcholine instillation immediately after the acetic acid exposure, almost complete prevention of the colitis could be obtained. Similarly, 50 mg phosphatidylinositol in each instillation with the first administration immediately after acetic acid administration resulted in complete prevention of the colitis and a significant decrease in mucosal permeability expressed as a plasma exudation into the colonic lumen. Similar results were obtained when phosphatidylcholine was administered immediately after acetic acid, but the drug then had to be applied twice daily. In contrast, a single application of the same total dose (150 mg) of the two different phospholipids, either 30 min before or immediately after acetic acid administration, could not prevent the development of colitis. It is concluded that both phosphatidylcholine and phosphatidylinositol have a therapeutic effect on the development of acetic acid-induced colitis in the rat.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1289171     DOI: 10.1159/000200969

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  14 in total

Review 1.  Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?

Authors:  P R Gibson; J G Muir
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

Review 2.  New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease.

Authors:  Darla R Shores; David G Binion; Bruce A Freeman; Paul R S Baker
Journal:  Inflamm Bowel Dis       Date:  2010-12-03       Impact factor: 5.325

3.  Prostaglandin E₂ and polyenylphosphatidylcholine protect against intestinal fibrosis and regulate myofibroblast function.

Authors:  Angela C Baird; Frances Lloyd; Ian C Lawrance
Journal:  Dig Dis Sci       Date:  2015-01-29       Impact factor: 3.199

4.  Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis.

Authors:  W Stremmel; U Merle; A Zahn; F Autschbach; U Hinz; R Ehehalt
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

5.  Anti-inflammatory effects of phosphatidylcholine.

Authors:  Irina Treede; Annika Braun; Richard Sparla; Mark Kühnel; Thomas Giese; Jerrold R Turner; Elsa Anes; Hasan Kulaksiz; Joachim Füllekrug; Wolfgang Stremmel; Gareth Griffiths; Robert Ehehalt
Journal:  J Biol Chem       Date:  2007-07-18       Impact factor: 5.157

Review 6.  Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation.

Authors:  Hannah Schneider; Annika Braun; Joachim Füllekrug; Wolfgang Stremmel; Robert Ehehalt
Journal:  Int J Mol Sci       Date:  2010-10-25       Impact factor: 5.923

7.  TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells.

Authors:  Irina Treede; Annika Braun; Petia Jeliaskova; Thomas Giese; Joachim Füllekrug; Gareth Griffiths; Wolfgang Stremmel; Robert Ehehalt
Journal:  BMC Gastroenterol       Date:  2009-07-13       Impact factor: 3.067

8.  Lipidomic profiling in Crohn's disease: abnormalities in phosphatidylinositols, with preservation of ceramide, phosphatidylcholine and phosphatidylserine composition.

Authors:  Gavin W Sewell; Yusuf A Hannun; Xianlin Han; Grielof Koster; Jacek Bielawski; Victoria Goss; Philip J Smith; Farooq Z Rahman; Roser Vega; Stuart L Bloom; Ann P Walker; Anthony D Postle; Anthony W Segal
Journal:  Int J Biochem Cell Biol       Date:  2012-06-19       Impact factor: 5.085

9.  Maternal exposure to low levels of corticosterone during lactation protects against experimental inflammatory colitis-induced damage in adult rat offspring.

Authors:  Carla Petrella; Chiara Giuli; Simona Agostini; Valérie Bacquie; Manuela Zinni; Vassilia Theodorou; Maria Broccardo; Paola Casolini; Giovanna Improta
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

10.  Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression.

Authors:  Jessica Bauer; Gerhard Liebisch; Claudia Hofmann; Christian Huy; Gerd Schmitz; Florian Obermeier; Jürgen Bock
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.